There are key challenges To Inhibiting BTK

Bruton's tyrosine kinase (BTK) promotes the growth and survival of malignant B cells1


Sustained inhibition of BTK must be maintained at therapeutic concentrations in target tissues2

Challenge

BTK requires 100% inhibition that is maintained around the clock
because it is continuously synthesized2,3

Diagram of the continuous cycle of BTK synthesis with introduction of BTK inhibitorDiagram of the continuous cycle of BTK synthesis with introduction of BTK inhibitor
Challenge

BTK inhibitor concentrations need to be sustained across disease-relevant tissues
to prevent areas of unchecked disease2,4

Lymph nodes

Peripheral blood 
mononuclear cells (PBMCs)

Challenge

BTK must be selectively targeted to potentially limit adverse effects5

Diagram of inadvertent off-target binding by BTK inhibitor

BTK inhibitor

BTK

Other kinases
(eg, EGFR, HER4, TEC)

Powerful And
Sustained Responses

Efficacy

Demonstrated
Safety Profile

Safety
myBeiGene

Personalized Patient
Support Program

Patient Support